Corren Jonathan
Section of Clinical Immunology and Allergy, Department of Medicine, University of California, Los Angeles, 10780 Santa Monica Blvd., Suite 280, Los Angeles, California 90025, USA.
Discov Med. 2013 Apr;15(83):243-9.
Asthma is a common chronic disease characterized by intermittent chest symptoms, variable airways obstruction, and bronchial hyperresponsiveness. Research performed over the past one to two decades has sought to better understand the heterogeneous clinical nature of asthma. Whereas older attempts at phenotyping asthma emphasized the duality of allergic vs. non-allergic asthma, more recent non-biased analyses have attempted to cluster patients by a multitude of possible features, including age of onset, atopy, severity of airways obstruction, and requirement for medication. Examples of these phenotypes include early-onset mild allergic asthma, later-onset asthma associated with obesity, and severe non-atopic asthma with frequent exacerbations. The elucidation of asthma phenotypes has been further refined by including information regarding pathophysiologic mechanisms present in different groups. These groups, called endotypes, include examples such as aspirin-exacerbated respiratory disease and allergic bronchopulmonary mycosis. A growing understanding of these mechanistically distinct groups, along with the identification of relevant cellular or molecular biomarkers, is already showing promise as a way of predicting clinical response to various asthma therapies. As the number of targeted treatments for asthma continues to grow, physicians will have the opportunity to practice an individualized approach to diagnosis and treatment, which will hopefully improve asthma outcomes and quality of life for these patients.
哮喘是一种常见的慢性疾病,其特征为间歇性胸部症状、可变的气道阻塞和支气管高反应性。过去一二十年所开展的研究试图更好地理解哮喘的异质性临床本质。以往对哮喘进行表型分析时强调变应性哮喘与非变应性哮喘的二元性,而最近的无偏分析则尝试根据多种可能特征对患者进行聚类,包括发病年龄、特应性、气道阻塞严重程度以及药物需求。这些表型的例子包括早发型轻度变应性哮喘、与肥胖相关的晚发型哮喘以及频繁加重的重度非特应性哮喘。通过纳入不同组中存在的病理生理机制的信息,对哮喘表型的阐释得到了进一步完善。这些组被称为内型,包括阿司匹林加重性呼吸系统疾病和变应性支气管肺曲菌病等例子。对这些机制上不同的组的日益了解,以及相关细胞或分子生物标志物的识别,已显示出有望成为预测对各种哮喘治疗的临床反应的一种方法。随着针对哮喘的靶向治疗数量不断增加,医生将有机会采用个体化的诊断和治疗方法,有望改善这些患者的哮喘治疗效果和生活质量。